Remove Clinical Trials Remove Conditions Remove Extraction Remove Research and Development
article thumbnail

Ehave, Inc. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Cannabis Law Report

Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. ” About Ehave, Inc. Ehave, Inc. Email: ir@ehave.com.

article thumbnail

Press Release: This is the FIRST Public Psychedelics Company to Notch a Patent for Extracting Natural Psilocybin

Cannabis Law Report

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ohio Gives Another Shot at Expanding Qualifying Conditions

Veriheal

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision.

article thumbnail

Radicle Science and Open Book Extracts Announce New Alliance to Advance Consumer Trust and CBD Industry Validation

Cannabis Law Report

The new Radicle Science-OBX alliance fills an unmet need for rigorous scientific research in the cannabis industry and sets a new gold standard for CBD and minor cannabinoid product development.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455.

DEA 66
article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52